Drobniewski et al. (2002)
UK
|
Cohort study
Level: III-2
Quality: 19/26
Some risk of bias
|
N=90 MDR-TB patients
36 born in UK, 7 in Pakistan, 5 in India, 4 in Bangladesh, 20 in Africa, 4 in Europe, 1 each from USA, Australia, Philippines, Japan, Trinidad, Jamaica
All cases were resistant to at least isoniazid and RIF, and 29 and 33 cases were resistant to pyrazinamide and ethambutol, respectively
|
Inclusion
All mycobacterial cultures identified by the Public Health Laboratory Service, Mycobacterium Reference Unit, Scottish Mycobacteria Reference Laboratory, and PHLS Regional Centres for Mycobacteria
|
Treatment with at least three drugs to which the bacterium was susceptible
|
Treatment with fewer drugs to which the bacterium was susceptible
|
Median survival period
Chance of death
|
Lam et al. (2014)
Thailand
|
Retrospective chart review
Level: III-2
Quality: 18.5/26
Some risk of bias
|
N=190 RIF-resistant or MDR-TB patients
|
Inclusion
Patients with DST results demonstrating infection with RIF-resistant or MDR-TB who were registered for TB treatment during October 2004 – September 2008 at health facilities within the Thailand TBAactive Surveillance Network
Exclusion
Patients from health facilities operated by private practitioners, non-governmental organisations, or facilities serving solely as referral centres, patients with incomplete laboratory data and patients with NTM infection or a change in diagnosis
|
Treatment other than Category II
|
Category II treatment (streptomycin, isoniazid, ethambutol, RIF and pyrazinamide)
|
Odds for poor outcome (treatment fail, death)
|
Meyssonnier et al. (2014)
France
|
Retrospective cohort study
Level: III-2
Quality: 18/26
Some risk of bias
|
N=39 RIF-mono-resistant TB patients, data about treatment and outcome were available for 30 patients
19 males (49%), median age 43 years (IQR 29–58)
Foreign born 18 (46%)
|
Inclusion
All patients diagnosed with RIF-mono-resistant TB reported to the national network in France between 2005 and 2010
|
Treatment with antibiotics other than RIF
|
Treatment with RIF-containing antibiotic regimen
|
Health outcomes (recovery, lost to follow-up, death, relapse)
|
